OS THERAPIES INC (OSTX) Stock Price & Overview
NYSEARCA:OSTX • US68764Y2072
Current stock price
The current stock price of OSTX is 1.335 USD. Today OSTX is up by 6.8%. In the past month the price decreased by -23.31%.
OSTX Key Statistics
- Market Cap
- 56.123M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.14
- Dividend Yield
- N/A
OSTX Stock Performance
OSTX Stock Chart
OSTX Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OSTX. When comparing the yearly performance of all stocks, OSTX is a bad performer in the overall market: 79.79% of all stocks are doing better.
OSTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to OSTX. OSTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
OSTX Earnings
OSTX Forecast & Estimates
10 analysts have analysed OSTX and the average price target is 12.24 USD. This implies a price increase of 816.85% is expected in the next year compared to the current price of 1.335.
OSTX Groups
Sector & Classification
OSTX Financial Highlights
Over the last trailing twelve months OSTX reported a non-GAAP Earnings per Share(EPS) of -1.14.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -226.24% | ||
| ROE | -430.26% | ||
| Debt/Equity | 0 |
OSTX Ownership
OSTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.2 | 374.127B | ||
| AMGN | AMGEN INC | 15.51 | 188.572B | ||
| GILD | GILEAD SCIENCES INC | 15.93 | 175.711B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.7 | 112.769B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.36 | 81.989B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.38 | 43.4B | ||
| INSM | INSMED INC | N/A | 34.527B | ||
| NTRA | NATERA INC | N/A | 29.881B | ||
| BIIB | BIOGEN INC | 10.93 | 26.402B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.32 | 25.496B | ||
| MRNA | MODERNA INC | N/A | 20.576B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.173B | ||
| INCY | INCYTE CORP | 12.49 | 19.083B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OSTX
Company Profile
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Company Info
IPO: 2024-08-01
OS THERAPIES INC
15825 Shady Grove Road, Suite 135
Rockville MARYLAND US
Employees: 4
Phone: 14102977793
OS THERAPIES INC / OSTX FAQ
Can you describe the business of OS THERAPIES INC?
OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2024-08-01. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. Its lead asset, OST-HER2, is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH-sensitive silicone linkers (SiLinkers). Its clinical-stage cancer immunotherapy programs also include OST-AXAL for human papilloma virus (HPV)-associated cancers; OST-503 for non-small cell lung cancer (NSCLC) & glioblastoma; and OST-PSA for prostate cancer.
Can you provide the latest stock price for OS THERAPIES INC?
The current stock price of OSTX is 1.335 USD. The price increased by 6.8% in the last trading session.
What is the dividend status of OS THERAPIES INC?
OSTX does not pay a dividend.
What is the ChartMill rating of OS THERAPIES INC stock?
OSTX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of OS THERAPIES INC (OSTX)?
OS THERAPIES INC (OSTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
What is the market capitalization of OSTX stock?
OS THERAPIES INC (OSTX) has a market capitalization of 56.12M USD. This makes OSTX a Micro Cap stock.
What is the outstanding short interest for OS THERAPIES INC?
The outstanding short interest for OS THERAPIES INC (OSTX) is 5.1% of its float.